BioCentury
ARTICLE | Clinical News

DKN-01: Additional Phase I data

August 1, 2016 7:00 AM UTC

Data from 22 evaluable patients with relapsed or refractory esophageal cancer in Parts A and B of the 4-part, open-label, dose-escalation Phase I P102 trial showed that twice-monthly DKN-01 plus once-...